Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2023 | Tackling resistance to CAR-T in ALL

Nitin Jain • 7 Sep 2023

SOHO 2023

Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab CAR-T

Patients with acute lymphoblastic leukemia (ALL) who relapse following CD19-directed CAR-T therapy may be CD19-positive or CD19-negative, which can impact management of the disease. Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the consequences, and potential methods of prevention, of resistance to CAR-T in patients with ALL. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax

Nitin Jain • 10 Dec 2023

An ongoing Phase I trial evaluating AS-1763, a novel non-covalent BTKi, in B-cell lymphomas

Nitin Jain • 10 Dec 2023

Long-term outcomes of the iFCG regimen for firstline treatment of patients with IGHV-mutated CLL

Nitin Jain • 10 Dec 2023

Nivolumab + ibrutinib for patients with Richter’s transformation

Nitin Jain • 7 Sep 2023

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024